Profitability
Weight: 25%
C-
50
- 5yr Avg ROIC 12.5%
- Operating Margin Trend -4.50 pp/yr
VRTX
Vertex Pharmaceuticals Incorporated
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
Capital Efficiency
Weight: 15%
B
73
- 5yr Avg ROE 13.6%
- 5yr Share-Count CAGR -0.2%
Growth Quality
Weight: 25%
A
89
- 5yr Revenue CAGR 12.4%
- 5yr EPS CAGR 14.2%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
A+
97
- 5yr FCF Margin 25.7%
- 5yr FCF/NI Conversion 0.98x
Balance Sheet
Weight: 10%
A+
99
- Net Debt / EBITDA -0.55x
- Interest Coverage (EBIT/Int) 357.95x
- Altman Z-Score 11.51
Stability
Weight: 5%
C
55
- EPS Volatility (σ/μ) 0.52
- Piotroski F-Score 5
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.4 of 4 gurus held; 1 added; 3 trimmed.
- Holders
- 4
- Avg Δ position
- +137.1%
- New buys
- 0
- Full exits
- 0